duocarmycin B1: from Streptomyces sp. DO-89
ID Source | ID |
---|---|
PubMed CID | 15100413 |
CHEMBL ID | 322666 |
SCHEMBL ID | 19493153 |
MeSH ID | M0168422 |
Synonym |
---|
duocarmycin b1 |
CHEMBL322666 |
124325-93-5 |
1h-pyrrolo(3,2-f)quinoline-2-carboxylic acid, 8-bromo-2,3,6,7,8,9-hexahydro-4-hydroxy-2-methyl-1-oxo-6-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (2r-trans)- |
niosh/jv1200000 |
JV12000000 |
duocarmycin b(sub 1) |
SCHEMBL19493153 |
DTXSID50924782 |
methyl (2r,8s)-8-bromo-4-hydroxy-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3,7,8,9-tetrahydropyrrolo[3,2-f]quinoline-2-carboxylate |
1h-pyrrolo3,2-fquinoline-2-carboxylic acid, 8-bromo-2,3,6,7,8,9-hexahydro-4-hydroxy-2-methyl-1-oxo-6 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID87752 | In vitro anticellular activity against HeLa S3 cells 72 hr after administration of the compound | 1999 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20 | Synthesis and antitumor activity of water-soluble duocarmycin B1 prodrugs. |
AID201731 | In vivo antitumor activity against Sarcoma 180 at dose 0.5 mg/kg | 1999 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20 | Synthesis and antitumor activity of water-soluble duocarmycin B1 prodrugs. |
AID87751 | In vitro anticellular activity against HeLa S3 cells 1 hr after administration of the compound | 1999 | Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20 | Synthesis and antitumor activity of water-soluble duocarmycin B1 prodrugs. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 5 (55.56) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (22.22%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (77.78%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |